Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study

SIMSPe Group

Research output: Contribution to journalArticlepeer-review

Abstract

Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare 8-week glecaprevir/pibrentasvir treatment in a case-control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co-infections. About 131 incarcerated (Group A) and 131 free patients (Group B) were included. Mean age was 43.0 ± 9.6 years and 42.8 ± 9.9 in Group A and B, respectively (P = .74). SVR rates were 96.2% and 99.2% in Group A and Group B respectively (P = .21). Five drop-outs occurred in Group A, one in Group B. Incarceration, being PWIDs and OST were not associated with SVR reductions (CI 95%). In conclusion, imprisonment does not influence unplanned interruptions or SVR rates when receiving short-term therapies. Short schedules with pangenotypic regimens could be a good approach to hard-to-reach populations, such as incarcerated patients.

Original languageEnglish
Pages (from-to)271-275
Number of pages5
JournalLiver international : official journal of the International Association for the Study of the Liver
Volume41
Issue number2
DOIs
Publication statusPublished - Feb 1 2021

Keywords

  • case-control study
  • direct acting antivirals
  • Hepatitis C virus
  • incarcerated patients
  • prison settings

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study'. Together they form a unique fingerprint.

Cite this